Atlas Trials

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Clinical trial NCT07441460 · RECRUITING

Trial details

NCT number
NCT07441460
Sponsor
Shanghai JMT-Bio Inc.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Resectable HER2-positive Breast Cancer
Start date
2026-03-06
Primary completion
2034-08-07
Enrollment
1800

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.